Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.

Merck is playing catch-up in the category with Bayer and Ionis, as their antisense-based Factor XI inhibitor fesomersen has already shown efficacy against clotting, with no increase in bleeding ...

Spoiler alert: Three years into separate six-year deals with Bayer and Merck, demand for the contraceptives is even higher than originally forecast. From 4.7 million in 2012, the annual run rate ...

Bayer is vying for a third indication for its ... UPDATED: Thursday, Jan. 2 at 1:45 p.m. ET Shortly before the new year, Merck & Co. scored an approval for its potential blockbuster Winrevair ...

ZURICH, Jan 14 (Reuters) - Bayer (BAYGn.DE), opens new tab will focus ... category Exclusive: Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say 4:32 PM UTC · Updated ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

In the past six months, while AbbVie rose the most (3.3%), Merck declined the most (24.8%). Watch this space for regular pipeline and regulatory updates next week. AstraZeneca, AbbVie, Bayer ...

L.L. has acted as a consultant for Merck, Novartis, and Bayer, and has received grants from Pfizer, Bayer, Merck, and Novartis. D.C.B. has served on the steering committee as a consultant for Merck.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...